Replies to post #83498 on $heff's $tation of $tocks & $olid DD

[$heff]

$THLD..Threshold Pharmaceuticals Announces New Phase 1/2 Data on TH-302 in Glioblastoma to be Presented at the 2014 SNO Annual Meeting

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and Avastin® (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) held in Miami, Florida, from November 13-16, 2014.

Dates and times for each poster presentation are provided below.

The poster titled, "Phase 1/2 study of TH-302, investigational hypoxia-activated prodrug, and bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma" (Abstract #AT-12) is being presented from 7:30 PM - 9:30 PM Eastern Time on Friday, November 14, 2014.

The poster titled, "Pharmacodynamic biomarker assessments in a Phase 1/2 trial of the hypoxia-activated prodrug TH-302 and bevacizumab in bevacizumab-refractory recurrent glioblastoma" (Abstract #DD-02) is being presented from 7:30 PM - 9:30 PM Eastern Time on Friday, November 14, 2014.

The abstracts are now available at http://neuro-oncology.oxfordjournals.org/.

About TH-302
TH-302, an investigational hypoxia-activated prodrug, is designed to be activated under severe tumor hypoxic conditions, a hallmark of many cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood supply as a result of aberrant vasculature. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic.

TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic STS, and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer (the MAESTRO trial). Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. The FDA and the European Commission have granted TH-302 Orphan Drug Designation for the treatment of STS and pancreatic cancer. TH-302 is also being investigated in earlier-stage clinical trials of other solid tumors and hematological malignancies.

Threshold has a global license and co-development agreement for TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S.